Skip to content

Exploring Engagement With Remote Symptom Tracking for Depression (RADAR: Engage)

A Two-Armed Trial Exploring the Effects of In-App Components on User Engagement With a Symptom-Tracking System for Depression (RADAR: Engage)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04972474
Enrollment
150
Registered
2021-07-22
Start date
2021-04-07
Completion date
2021-09-30
Last updated
2021-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Brief summary

The aim of this study is to understand how best to promote engagement with remote measurement technology (RMT) research in major depressive disorder, using the RADAR-MDD infrastructure as a case study. An adapted questionnaire app with insightful notifications and progress visualization will be compared against the app as usual, in terms of behavioural and experiential engagement.

Detailed description

Remote measurement technologies (RMTs) provide an opportunity for real-time, longitudinal health tracking through a combination of smartphone apps for symptom reporting (active RMT; aRMT) and mobile/wearable sensors for passive data collection (passive RMT; pRMT). The use of RMTs to track relapse and remission of symptoms in major depressive disorder (MDD) is thought to be more reflective of patient daily experience, in comparison to retrospective recall during clinic visits. The Remote Assessment of Disease and Relapse- Major Depressive Disorder (RADAR-MDD) study uses RMTs to identify predictors of MDD relapse. It collects multiparametric RMT data through the RADAR-base system over a two year follow-up period; aRMT data is collected via mood-tracking questionnaires in the active app, and pRMT data is collected via a fitness watch, the Fitbit Charge device. The promise of RADAR-MDD depends heavily on user engagement with the app. Currently, engagement with aRMT symptom tracking in the field is hugely heterogeneous and preliminary estimates of the RADAR-MDD study suggest around 50% completion of fortnightly questionnaires. There are several, in-app methods available to promote engagement with mHealth tools. Notifications with theoretically informed content can provide a trigger to perform a behaviour, and data visualisation of progress can prompt continued data input. It is unclear which combination of in-app features can promote engagement with the RADAR-base system, while minimising participant burden. This study therefore aims to understand how best to promote engagement with RMT research, using the RADAR-MDD project as a case study. This protocol will outline a mixed-methods approach to exploring the impact of additional, in-app components on engagement with symptom tracking via the RADAR-Base infrastructure. First, a two-armed randomized controlled trial will compare the RADAR-MDD questionnaire app as usual with an adapted app with insightful notifications and progress visualization, aimed at promoting behavioural and experiential engagement. Engagement will be measured as a) provision of symptom tracking scores over the 12-week study period, and b) the degree to which participants feel experientially engaged with symptom tracking via the system. Second, qualitative interviews will reveal participant experiences of the techniques used. The study has three main objectives: To examine the impact of an adapted smartphone app on behavioural engagement with RMT symptom tracking, in comparison with the RADAR-MDD app as usual; To examine the impact of an adapted smartphone app on experiential engagement with RMT symptom tracking, in comparison with the RADAR-MDD app as usual; Qualitatively explore the views of participants on the use of an adapted smartphone app to increase engagement with the RADAR-Base system. Findings in this field would go some way to providing scalable solutions for engagement in RMT studies, higher quality results and applications for implementation into clinical practice.

Interventions

OTHERSmartphone app in-app components

Insightful notification text, data visualisation, research team contact details.

Sponsors

King's College London
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Masking description

Participants are unaware of the changes that have been made to the app, and therefore are unaware of which arm they are randomised to.

Intervention model description

Participants will be randomised to one of two arms, the app as usual or the adapted app.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Participation in the RADAR-MDD London site study * Consent for future research contact given during participation in the RADAR-MDD study * Willing and able to continue using an Android smartphone * Willing and able to continue using a Fitbit device * Capacity to give informed consent

Exclusion criteria

* Development of a comorbid psychiatric disorder since participation in the RADAR-MDD study

Design outcomes

Primary

MeasureTime frameDescription
Behavioural engagementTotal completion at the 12-week end pointData completion of active symptom tracking (PHQ-8 scale). Value of 0-12.

Secondary

MeasureTime frameDescription
Experiential engagement (1)Baseline and 12-week pointUser Engagement Scale for mHealth Technology. 30 items, 5-point likert scale. Minimum value 0, maximum value 150. Higher value relates to increased experiential engagement.
Experiential engagement (2)Baseline and 12-week pointEmotional Self-Awareness Questionnaire. 33 items, 5-point likert scale. Minimum value 0, maximum value 165. Higher value relates to increased emotional awareness.
System UsabilityBaseline and 12-week pointmHealth App Usability Questionnaire. 18 items, 7-point likert scale. Minimum value 0, maximum value 126. Higher value relates to increased app usability rating.
Passive monitoring adherenceContinuously across a 12-week time periodFitbit device weartime

Countries

United Kingdom

Contacts

Primary ContactKatie White, BSc
katie.white@kcl.ac.uk07850 684847

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026